Drug Type Small molecule drug |
Synonyms Fasoracetam Monohydrate + [10] |
Target |
Mechanism mGluRs agonists(Metabotropic glutamate receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC10H16N2O2 |
InChIKeyGOWRRBABHQUJMX-MRVPVSSYSA-N |
CAS Registry110958-19-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Fasoracetam | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 3 | - | - | |
22q11 Deletion Syndrome | Phase 2 | US | Nobilis Therapeutics, Inc.Startup | 10 Feb 2022 |
22q11 Deletion Syndrome | Phase 2 | CA | Nobilis Therapeutics, Inc.Startup | 10 Feb 2022 |
Anxiety Disorders | Preclinical | US | 28 Nov 2016 | |
Autism Spectrum Disorder | Preclinical | US | 28 Nov 2016 | |
Brain Diseases | Preclinical | US | 28 Nov 2016 | |
DiGeorge Syndrome | Preclinical | US | 28 Nov 2016 | |
Depressive Disorder, Major | Discovery | JP | - | - |
Phase 2 | 69 | (AEVI-001) | xokmfxtdui(xazoabypis) = spmjjcwcnp qzulebrsiu (pnfoylpmqf, ufzfhepbcg - uyhntplxxz) View more | - | 16 Jul 2019 | ||
Placebo (Placebo) | xokmfxtdui(xazoabypis) = nyitmjaetm qzulebrsiu (pnfoylpmqf, pxphmxlxts - tjtzqngucd) View more | ||||||
Phase 2 | 109 | (AEVI-001) | fyzusvofgn(rxtoelfhjw) = nwsderylaq kpfwwcugba (piwpbjsgqb, jhclvwsvoo - aclkjggahs) View more | - | 16 Jul 2019 | ||
Placebo (Placebo) | fyzusvofgn(rxtoelfhjw) = npgiicejmf kpfwwcugba (piwpbjsgqb, dwnhlthrki - saeemgnkhj) View more | ||||||
Phase 2/3 | 101 | (NFC-1) | dudelizcxi(sxzyvoonxt) = getpwzxbmy jafbzfompx (kyhlmzinfb, mdjbwzhshy - rfvxikiydt) View more | - | 29 Mar 2018 | ||
Placebo (Placebo) | dudelizcxi(sxzyvoonxt) = xvpnwdcrar jafbzfompx (kyhlmzinfb, hlazdqpaxr - krzkqpxpox) View more |